Allergen sensitisation tests under development

Assay developer Angsana Molecular & Diagnostics Laboratory has announced that it will provide tests for allergen sensitisation specific for the Asian population. The tests will be based on Thermo Fisher Scientific’s ImmunoCAP technology and performed on its Phadia Laboratory Systems.

While many allergens are common across populations, there has been increased recognition of differences in the prevalence and morbidity of atopic diseases among different ethnic groups and across different geographic regions. Angsana is seeking to define and validate specific tests for allergen sensitisation that are suited to local needs.

“With the rising incidence of atopic diseases, particularly among younger children, it is important to better understand the regional and ethnic differences in Asian countries,” said Dr Richard Choy, Angsana’s chief scientific officer and managing director of the company’s Hong Kong laboratory. “Through collaboration with local medical experts and healthcare providers, Angsana aims to provide a testing solution for Asia, in order to help improve the diagnosis efficiency and aid better allergy management.”

ImmunoCAP technology is said to feature high specificity and sensitivity, enabling quantitative results due to a comprehensive menu of allergens and allergen components. Stefan Wolf, president of ImmunoDiagnostics at Thermo Fisher, said he was pleased that the company’s technology could be used to support Angsana’s efforts.